Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKM + Neoadjuvant Chemotherapy in TNBC
NCT04081389Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2019
- Primary completion
- May 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rintatolimod, celecoxib oral solution and interferon alfa-2b in triple-negative breast cancer (TNBC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Dose Limiting Toxicities at 21 days. Started Dec 2019; status: completed.
02
Drugs
rintatolimodcelecoxib oral solutioninterferon alfa-2b
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04081389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081389.